Cardiology in New Jersey

Vision RT Limited is the market leader in Surface Guided Radiation Therapy (SGRT), a 3D surface imaging technology that tracks patient position and motion throughout the entire radiotherapy workflow to improve safety, effectiveness, and efficiency of cancer treatment. The company offers an integrated suite of solutions spanning simulation, planning, treatment, and dose verification. SimRT is a single-camera contactless system for 4D and breath-hold CT monitoring during the simulation phase, eliminating the need for physical surrogates and demonstrating 3x greater accuracy than traditional methods. MapRT is a dual-camera solution that maps safe beam angles during treatment planning to improve plan quality and deliverability while the patient is in the CT room. AlignRT is the flagship real-time motion management system for the treatment room, available in standard and InBore configurations, with specialized modules for patient ID verification, respiratory gating, stereotactic radiosurgery, and postural coaching. DoseRT leverages Cherenkov-enabled imaging to visualize radiation delivery in real-time and detect dose errors, reducing secondary cancer risk. Vision RT systems are deployed in over 3,000 oncology clinics globally, including 24 of the top 25 U.S. cancer hospitals. The technology supports all cancer types including breast, prostate, lung, liver, head and neck, brain, and sarcoma, with specialized applications for proton therapy, deep inspiration breath hold, stereotactic radiosurgery, and pediatric patients. AlignRT reduces treatment times by an average of 22% per fraction. The company has published extensively in peer-reviewed journals and holds regulatory clearances for clinical use. Vision RT operates with approximately 25 years of SGRT expertise and maintains UK-based operations.

Therakos LLC manufactures the THERAKOS® CELLEX® Photopheresis System, an FDA-approved extracorporeal photopheresis (ECP) device for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) unresponsive to other therapies. The system performs ultraviolet-A (UVA) irradiation of leukocyte-enriched blood in the presence of 8-methoxypsoralen (8-MOP), with co-administered pharmaceutical UVADEX® (methoxsalen) sterile solution. The company provides a complete therapeutic platform including the photopheresis system hardware, consumables, operator training through the Therakos Institute, and comprehensive customer support services branded as Therakos Total Care. The system is designed for use in clinical settings where standard medical emergency equipment and volume management capability are available. Following acquisition by CVC, certain operations continue under transition services agreement with Mallinckrodt Pharmaceuticals. Therakos markets primarily to hematology-oncology centers, dermatology departments, and specialized treatment centers managing CTCL patients. The company maintains dedicated business manager support and professional education programs for treating physicians and clinical staff. Product indications and contraindications are clearly defined with specific patient selection criteria and comprehensive safety protocols documented in the operator's manual and UVADEX prescribing information.

Berman Medical Lasers International specializes in Class 4 therapeutic laser systems for pain management, injury treatment, and tissue healing across multiple clinical disciplines. The company manufactures continuous-wave 980 nm infrared diode lasers in two primary product lines: table-top models available in 30, 45, and 60-watt configurations, and portable models in 10, 15, 20, and 30-watt options. All systems feature dual handpieces with optional specialized handpieces for nail/wart treatment and surgical ablation. Power ranges from 0.5 to 60 watts depending on model. Products are supplied as new and refurbished units. The lasers are designed for photobiomodulation therapy, utilizing photon energy absorption through skin to stimulate cellular rejuvenation and promote oxygenation-driven healing of damaged nerves, tissues, and cells. Clinical applications include treatment of fungal infections, skin conditions, warts, wounds, inflammation, neuropathic pain, nail disorders, and muscle pain. Target markets include podiatry, chiropractic, dental, physical therapy, massage therapy, acupuncture, veterinary medicine, and physical medicine practices. The company emphasizes sustained clinical outcomes and rapid treatment times, with laser cost reductions of 50% available under Section 179 tax provisions. Berman offers a 100% 30-day money-back guarantee and 50% refund within 180 days, plus trade-up options within 24 months. The company maintains a consultant-driven sales model with personalized needs assessment and has built a customer base of thousands of practitioners.

Becton, Dickinson and Company (BD) is a global medical technology leader founded in 1897 with approximately $20.2 billion in FY2024 revenue. BD supplies a comprehensive portfolio spanning diagnostic and laboratory solutions, surgical products and instruments, medication management systems, and infection prevention technologies. The company pioneered disposable syringes (Plastipak™) and blood collection systems (BD Vacutainer®), and operates automated blood culture and diagnostic platforms. Through strategic acquisitions including CareFusion and C.R. Bard, BD expanded capabilities in medication management, surgical interventions, and hospital systems. Current offerings address ambulatory surgery centers, diagnostic accuracy and specimen collection workflows, patient safety and infection control, advanced clinical analytics through BD HealthSight Advisor, medication management optimization, and surgical efficiency. BD Incada™ Connected Care Platform represents the company's digital health integration strategy. With global operations across alternate sites, diagnostic labs, research areas, hospital units, pharmacy, and surgical suites, BD serves healthcare systems seeking integrated solutions to improve patient outcomes and operational efficiency.

Bio Compression Systems, Inc. is a US-based manufacturer of pneumatic compression devices designed to treat lymphatic and circulatory disorders. The company specializes in sequential compression pumps that employ non-peristaltic action to mimic the body's natural lymphatic function, reducing swelling, decreasing pain, and improving range of motion and mobility. Product applications include lymphedema management, lipedema, venous and arterial insufficiency, wound care support, DVT prophylaxis, post-operative recovery, sports medicine, phlebolymphedema, and peripheral arterial disease (PAD). Bio Compression devices are engineered for both clinical hospital settings and home use, featuring sleek, quiet, lightweight, and portable designs with user-friendly operation. The company markets to healthcare providers, durable medical equipment (DME) suppliers, physical therapists, and individual patients. Multiple product lines (SC-2004-OC, SC-3008-DL, SC-3004-DL, SC-2008-OC, VascuEase, IC-BAP, IC-1545) serve different anatomical regions and clinical needs. The company also offers compression garments as complementary products. Bio Compression maintains a direct sales model with patient education and clinical support; patient testimonials document significant reductions in limb circumference, improved functional mobility, reduced pain, and enhanced quality of life. Manufacturing and customer support are located in Moonachie, NJ.

3T Medical Systems, Inc. (founded 1998) is a US-based medical device distributor and manufacturer specializing in surgical support equipment and clinical consumables. The company serves anesthesiologists, operating room nurses, sterile processing staff, infection prevention specialists, and surgeons performing specialized surgical procedures. 3T Medical operates a large distribution facility in the Midwest and a sales office in the Mid-Atlantic region, serving both domestic and international healthcare markets. The company's primary product lines include blood management systems (CONSTAVAC™ CBCII System for intraoperative blood reinfusion), anesthesia and laryngoscopy equipment, regenerative medicine products, and precision temperature management systems (Altrix, acquired from Stryker in 2025). 3T Medical also acquired Enterix, Inc. in 2022, expanding its portfolio in regenerative medicine and wound care solutions. 3T Medical holds ISO 13485:2016 certification, demonstrating compliance with international medical device quality management standards. The company focuses on reducing healthcare costs while improving patient outcomes through specialized equipment designed for complex surgical environments and perioperative care. Products are distributed to hospitals, surgical centers, and clinical institutions requiring blood management, temperature control, and anesthesia support capabilities.

Professional Surgical Instruments Co., Inc. is a comprehensive manufacturer and distributor of surgical instruments serving the global medical, dental, and veterinary markets. Based in East Brunswick, New Jersey, the company specializes in precision-engineered stainless steel surgical instruments across multiple specialties. Their extensive product portfolio includes forceps, needle holders, scissors, retractors, clamps, elevators, rongeurs, and specialized instruments for cardiothoracic, orthopedic, neurosurgical, laparoscopic, microsurgical, ophthalmic, ENT, OB/GYN, dermatology, plastic surgery, and pediatric procedures. The company also manufactures dental surgical instruments, endodontic tools, orthodontic instruments, periodontal instruments, and restorative dental tools. Products are available in both individual instruments and pre-assembled surgical sets. Professional Surgical Instruments maintains a B2B focus, offering medical device manufacturing expertise and a detailed surgical instrument catalog to hospitals, surgical centers, dental practices, and veterinary clinics worldwide.

CytoSorbents, Inc. is a medical technology company specializing in hemoadsorption blood purification therapy. The company develops extracorporeal adsorption devices based on proprietary biocompatible polymer bead technology designed to reduce elevated levels of potentially harmful compounds from whole blood. The primary product, CytoSorb 300®, is an adsorber that complements conventional dialysis approaches and is used in critical care, cardiovascular, liver, and kidney therapeutic areas. CytoSorbents also offers PuriFi, an independent therapy platform enabling standalone CytoSorb® use; ECOS-300CY for ex vivo organ perfusion applications; and VetResQ for veterinary critical-care applications. The company maintains a global presence in over 75 countries and provides clinical support through a team of specialists. Products are CE-marked and available internationally, though CytoSorb 300® and related human therapeutics are not authorized or cleared in the US market. VetResQ is available only in the US. The company positions itself as a trusted partner for advanced blood purification technologies in settings where physiological balance and management of inflammatory or harmful substances is critical.

Mirion Technologies is a global provider of radiation detection, measurement, and safety solutions serving nuclear power operations, medical imaging and cancer care, occupational dosimetry, and environmental radiochemistry. The company specializes in radiological instrumentation, personal and area dosimetry products, radiation survey monitoring equipment, and supervisory software platforms. Key product lines include the Vital® Supervision platform (centralized radiological instrumentation management), CSPevo® Probe Family (portable radiation survey monitoring), Instadose®VUE (wireless personal dosimeters), and FRAM isotopic analysis systems. Mirion serves nuclear utilities, medical oncology centers, radiopharmaceutical manufacturers, research institutions (including the IAEA), and government agencies including NASA. The company provides training courses in radiation measurement and equipment operation, hosts industry conferences (Mirion Connect), and maintains service and support capabilities across multiple markets. Recent acquisitions and partnerships (Paragon Energy Solutions, Certrec) expand capabilities in nuclear licensing and infrastructure. Mirion's dosimetry products are used by healthcare workers and space program personnel (NASA Artemis missions).

Nyxoah is a medical technology company specializing in the development and commercialization of innovative solutions for obstructive sleep apnea (OSA) treatment. The company's flagship product is the Genio® system, a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy designed to treat OSA, the world's most common sleep-disordered breathing condition. OSA affects approximately 936 million people globally between ages 30–69, with 425 million suffering from moderate to severe cases requiring treatment. Left untreated, OSA is associated with significant morbidity and mortality, including doubled stroke risk, five-fold increased cardiovascular mortality, and a 140% increased risk of heart failure. The Genio® system offers an alternative to traditional continuous positive airway pressure (CPAP) therapy, addressing the substantial unmet clinical need in sleep medicine. Nyxoah is actively expanding operations and commercializing its lead solution across multiple markets. The company maintains a focus on clinical evidence and patient outcomes in treating this major sleep-disordered breathing condition with significant cardiovascular and systemic implications.

Konica Minolta is a diversified imaging technology company offering comprehensive healthcare IT and medical imaging solutions through its Healthcare Americas division. The company provides advanced digital imaging systems and integrated IT solutions that support the patient journey from diagnosis through treatment. Healthcare offerings include diagnostic imaging equipment, clinical software, and managed IT infrastructure services tailored to healthcare organizations. Beyond medical, Konica Minolta operates major business units in digital office printing, production and industrial printing, IT management services, measuring instruments for quality control, imaging IoT technology, textile printing, and security services. The company demonstrates significant R&D capabilities in optical and digital technologies, with manufacturing and service infrastructure supporting North American markets. Konica Minolta holds relevant certifications and regulatory approvals for medical device operations, though specific certifications are not detailed on the homepage. The organization serves enterprise and institutional clients across healthcare, printing, industrial, and technology sectors.

Infusyn Therapeutics manufactures the Prometra II, an implantable, fully programmable drug delivery system designed for precise, targeted therapeutic administration. The Prometra II features Infusyn's proprietary Precision Dosing System (PDS), engineered to deliver medication with exceptional accuracy while minimizing variability from reservoir volume, temperature, and pressure fluctuations. Currently FDA-approved for pain and spasticity management, the system enables physicians to achieve individualized, flexible dosing regimens with unrivaled consistency. Infusyn is expanding Prometra applications across multiple therapeutic indications through strategic partnerships, including development for pulmonary arterial hypertension (PAH). The company serves hospital systems, specialty clinics, and pain management centers requiring implantable infusion solutions with superior dosing reliability and patient-centric programmability.

Infervision is a global medical artificial intelligence company founded in 2015, specializing in deep learning technologies for medical imaging and clinical diagnostics. Headquartered in Beijing with a US office in Lyndhurst, New Jersey, Infervision develops AI-powered platforms designed for radiologists and clinicians to enhance diagnostic accuracy and clinical workflows. The company's InferRead™ suite processes over 33,000 exams daily and provides comprehensive imaging analysis across multiple organ systems including lungs, cardiovascular, breast, and bone. InferOperate™ offers surgical planning and intraoperative navigation, while InferScholar™ and InferMatrix™ platforms support medical research and innovation. Infervision's solutions assist in detecting conditions such as lung cancer, stroke, pneumonia, tuberculosis, and fractures from various imaging scans. The company holds regulatory approvals from the US FDA, China NMPA, EU CE, UK UKCA, and Japan PMDA, with products deployed across 1,000+ medical institutions in 30+ countries.

AGFA HealthCare is a global leader in enterprise imaging and diagnostic imaging software solutions serving healthcare organizations worldwide. The company develops and delivers an integrated Enterprise Imaging platform that consolidates PACS (Picture Archiving and Communication Systems), imaging analytics, and clinical workflows across multiple imaging modalities including radiology, cardiology, breast imaging, molecular imaging, digital pathology, POCUS (point-of-care ultrasound), teleradiology, medical photography, and specialty areas including dental, ophthalmology, and orthopedics. The Enterprise Imaging platform is engineered around clinician-first design principles, offering seamless workflow integration, blazing-fast streaming access, and specialty-tailored clinical workspaces. Key product components include: Streaming Client (web-based diagnostic access), XERO Universal Viewer (patient-centric cross-specialty imaging), Vendor Neutral Archive (VNA) for multimedia data consolidation, RUBEE AI (augmented intelligence ecosystem), RUBEE Orchestrator (workflow automation and orchestration), Business Intelligence tools, and Enterprise Imaging Scheduling. AGFA HealthCare delivers solutions across multiple deployment models: on-premises, cloud (SaaS), and hybrid architectures, utilizing cloud-native microservices. The platform is built with security-by-design principles, incorporating encryption, access control, auditing, and compliance frameworks. The company serves hospitals, health networks, and healthcare organizations of varying digital maturity and scale, from individual facilities to large enterprise systems. Services include hands-on onboarding, role-specific training programs, clinical coaching, customer experience center collaboration, CE credit programs, and 24/7 operational support. AGFA HealthCare has received recognition as "Best in KLAS" for 2026 across multiple enterprise imaging segments and maintains established partnerships and deployments globally.

Corza Medical is a global medical technology company with $500M+ in annual revenue, 3,000+ employees, and operations in 80+ countries. The company manufactures and distributes surgical consumables, wound closure solutions, biosurgery products, biomedical textiles, and ophthalmic instruments through multiple product lines and acquired brands. Primary product portfolios include: Quill barbed sutures for wound closure; TachoSil and TachoComb hemostasis/sealing matrices for surgical hemostasis; Sharpoint sutures and surgical knives; Katena ophthalmic microsurgical instruments and accessories; Pearsalls biomedical textiles for OEM partners; and specialty suture products (Express Gut, Look, Blink). The company operates manufacturing facilities across seven global locations including the United States, Europe, China, and Mexico. Corza Medical serves hospitals, surgical centers, and healthcare providers across general surgery, ophthalmology, wound closure, and biosurgery specialties. The company emphasizes regulatory compliance, quality assurance, and medical education support. It maintains headquarters in Boulder, CO (Global), Zurich, Switzerland (EMEA), and Shanghai, China, with additional operational facilities in Michigan, Missouri, Pennsylvania, Germany, the United Kingdom, and Mexico. Corza Medical was recognized in the 2024 MedTech Big 100 list and received the 2024 Global Excellence Award for innovative wound closure solutions.

LifeSign LLC is a medical diagnostic company specializing in high-quality rapid point-of-care (POC) testing solutions for the healthcare industry. The company manufactures and distributes a comprehensive portfolio of diagnostic test kits and reagents across multiple clinical specialties, including infectious disease, women's health, cardiac care, urology, gastrointestinal health, drugs of abuse screening, hygiene, and industrial applications. Key product lines include the Status™ rapid test platform, covering COVID-19/Flu A&B multiplex testing, influenza B, mononucleosis, and strep A detection. LifeSign serves hospitals, clinics, urgent care centers, and other healthcare facilities requiring rapid, reliable diagnostic results at the point of care. The company emphasizes early detection and rapid diagnosis to improve clinical outcomes. LifeSign maintains manufacturing and quality systems appropriate for medical device distribution, with products distributed through a national sales and support network. The organization is positioned as a B2B supplier of diagnostic consumables and testing solutions for various medical markets.